安科生物(300009.SZ):擬1031.56萬元受讓鑫華坤公司合計11.32%股權
格隆匯12月12日丨安科生物(300009.SZ)公佈,為優化子公司治理結構,提高經營決策效率,公司擬使用自有資金人民幣1031.56萬元受讓宋禮華先生、宋禮名先生、原春寧女士、範清林先生、宋社吾先生、姚建平先生、盛海先生、嚴新文先生、汪永斌先生(上述統稱“轉讓方”,下同)合計持有的安徽鑫華坤生物工程有限公司(簡稱“鑫華坤公司”)11.32%的股權。截至目前,公司與轉讓方尚未簽署協議。待本次交易完成後,公司持有鑫華坤公司股權將由49.85%變更為61.16%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.